World's Best Scientists 2026 revealed!
Mark R. Litzow

Mark R. Litzow

D-Index & Metrics

Medicine

D-Index
123
Citations
55915
World Ranking
3356
National Ranking
1845

Mark R. Litzow publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark R. Litzow sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 1,016 publications — 95th percentile

95% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark R. Litzow D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark R. Litzow sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 123 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Mark R. Litzow is affiliated with the Mayo Clinic in the United States and has a significant research footprint in the field of medicine, particularly within hematology. Their research encompasses various subfields, including genetics, public health, environmental and occupational health, molecular biology, and oncology.

The main topics of Mark R. Litzow's work include:

  • Acute Myeloid Leukemia Research
  • Chronic Myeloid Leukemia Treatments
  • Acute Lymphoblastic Leukemia Research
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Hematopoietic Stem Cell Transplantation
  • Chronic Lymphocytic Leukemia Research
  • CAR-T Cell Therapy Research

Mark R. Litzow has contributed to publications in several key venues. The most frequent publication venues include:

  • Blood
  • Transplantation and Cellular Therapy
  • Blood Advances
  • American Journal of Hematology
  • Blood Cancer Journal

Some notable recent papers featuring Mark R. Litzow include:

  • Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, 2021, Journal of the National Comprehensive Cancer Network
  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial, 2022, Blood
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial, 2020, Nature Medicine
  • American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults, 2020, Blood Advances
  • Palliative Care for Patients With Cancer: ASCO Guideline Update, 2024, Journal of Clinical Oncology

Frequent co-authors who have collaborated extensively with Mark R. Litzow include:

  • Hassan B. Alkhateeb
  • William J. Hogan
  • Mrinal M. Patnaik
  • Mithun Vinod Shah
  • Aref Al-Kali

Best Publications

  • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

    Jay P. Patel;Mithat Gönen;Maria E. Figueroa;Hugo Fernandez

  • Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.

    Max S. Topp;Nicola Gökbuget;Anthony S. Stein;Gerhard Zugmaier

  • MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

    Animesh D. Pardanani;Ross L. Levine;Terra Lasho;Yana Pikman

  • Anthracycline Dose Intensification in Acute Myeloid Leukemia

    Hugo F. Fernandez;Zhuoxin Sun;Xiaopan Yao;Mark R. Litzow

  • Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

    Hagop M. Kantarjian;Francis Giles;Norbert Gattermann;Kapil Bhalla

  • In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

    Anthony H. Goldstone;Susan M. Richards;Hilliard M. Lazarus;Martin S. Tallman

  • Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL

    Jennifer A Woyach;Amy S Ruppert;Nyla A Heerema;Weiqiang Zhao

  • Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

    Adele K. Fielding;Susan M. Richards;Rajesh Chopra;Hillard M. Lazarus

  • Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993

    Jacob M. Rowe;Georgina Buck;Alan Kenneth Burnett;Raj Chopra

  • Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

    Voravit Ratanatharathorn;Richard A. Nash;Donna Przepiorka;Steven M. Devine

  • Risk factors for acute GVHD and survival after hematopoietic cell transplantation.

    Madan Jagasia;Mukta Arora;Mary E D Flowers;Nelson J. Chao

  • Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

    Tait D. Shanafelt;Xin V. Wang;Neil E. Kay;Curtis A. Hanson

  • International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.

    Andrew C. Harris;Andrew C. Harris;Rachel Young;Rachel Young;Steven Devine;William J. Hogan

  • First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation.

    Paul J. Martin;J. Douglas Rizzo;John R. Wingard;Karen Ballen

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial

    Anthony V. Moorman;Christine J. Harrison;Georgina A.N. Buck;Sue M. Richards

  • Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure

    Michel Duval;John P. Klein;Wensheng He;Jean Yves Cahn

  • Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

    Alexander E. Perl;Jessica K. Altman;Jorge Cortes;Catherine Smith

  • Hematologic manifestations of celiac disease.

    Thorvardur R. Halfdanarson;Mark R. Litzow;Joseph A. Murray

  • Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

    Morie A. Gertz;Martha Q. Lacy;Angela Dispenzieri;Philip R. Greipp

  • Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia

    A Moorman;C J Harrison;Buck Gan.;S M Richards

Frequent Co-Authors

Hillard M. Lazarus
Hillard M. Lazarus Case Western Reserve University
Morie A. Gertz
Morie A. Gertz Mayo Clinic
Martha Q. Lacy
Martha Q. Lacy Mayo Clinic
Ayalew Tefferi
Ayalew Tefferi Mayo Clinic
Martin S. Tallman
Martin S. Tallman Northwestern University
David J. Inwards
David J. Inwards Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

There are many online programs designed to support individuals pursuing medical and healthcare careers in the USA. As demand grows for skilled healthcare professionals, online degrees offer flexibility and affordability for students balancing work, family, or other commitments. Specializing in health administration, pharmacy, nursing, or information management can open up new pathways within the healthcare sector.

For those interested in administrative roles, the cheapest online mha programs can help you gain leadership and management skills essential for running healthcare facilities. If advanced nursing is your interest, you might consider the cheapest dnp programs to pursue your Doctor of Nursing Practice online at a lower cost.

Aspiring pharmacists can explore the cheapest online pharmacy school options, which prepare graduates for vital roles in medication management and patient care. Additionally, technology-focused students can opt for online rhit degree programs to enter the high-demand field of health information management.

Choosing the right online degree not only keeps costs down but also broadens your career opportunities, allowing you to make a meaningful impact in healthcare.

Best Scientists Citing Mark R. Litzow

Trending Scientists

Recently Published Articles